BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive ...
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $63.00 price ...
The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $58.6, along ...
The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...
CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...
Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 393.3% during the 4th quarter, according to its most recent Form 13F ...
He is a co-founder of Digital Harmonic and Brahm Astra Therapeutics. Elisseeff is founder of Aegeria Soft Tissue. Powell is an employee of Calico but was not when this research was performed. Pardoll ...